Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
Cash from Financing Activities
Cyclopharm Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cash from Financing Activities
-AU$1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
2%
|
Neurotech International Ltd
ASX:NTI
|
Cash from Financing Activities
AU$9.4m
|
CAGR 3-Years
250%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
ASX:IPD
|
Cash from Financing Activities
AU$28m
|
CAGR 3-Years
3%
|
CAGR 5-Years
192%
|
CAGR 10-Years
N/A
|
|
Cochlear Ltd
ASX:COH
|
Cash from Financing Activities
-AU$377.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-21%
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash from Financing Activities
AU$16.2m
|
CAGR 3-Years
21%
|
CAGR 5-Years
140%
|
CAGR 10-Years
54%
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash from Financing Activities
AU$2.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
See Also
What is Cyclopharm Ltd's Cash from Financing Activities?
Cash from Financing Activities
-1m
AUD
Based on the financial report for Dec 31, 2023, Cyclopharm Ltd's Cash from Financing Activities amounts to -1m AUD.
What is Cyclopharm Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
2%
Over the last year, the Cash from Financing Activities growth was -40%. The average annual Cash from Financing Activities growth rates for Cyclopharm Ltd have been -1% over the past three years , -24% over the past five years , and 2% over the past ten years .